Sharemaestro company-news research for Zymeworks Inc. Common Stock (ZYME), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest ZYME news and sentiment
Zymeworks Inc. Common Stock
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
13 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone38/100
→
Published 30-day score48/100
Latest source headline
Zymeworks (ZYME) Sets 2026 Revenue Guidance, Is The Stock Below Fair Value?
Simply Wall Street · 12 Oct 2026 08:50
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
13 current stories are mapped specifically to ZYME.
The score uses 3 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.183.
Confidence is 25/100, below the threshold for a firm score.
48/100
News scoreEarly balanced news score
25/100
Confidencethin evidence
94%/100
Company news13 company stories
78/100
Story agreement22/100 difference
News history
Daily score and story count over 30 days
17 Sep02 Oct16 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence4
0.183 after freshness weightingSource breadth60
3 independent publishersCompany relevance94
share tied directly to this companyFreshness30
recency-weighted evidenceAgreement78
how closely stories agreePublisher mix44
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks21 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202652USD 25.79+2.5%
02 Oct 202654USD 25.15-5.2%
25 Sep 202650USD 26.52-0.2%
18 Sep 202651USD 26.57+1.3%
11 Sep 202652USD 26.24-10.1%
04 Sep 202653USD 29.19+3.3%
28 Aug 202656USD 28.27-1.4%
21 Aug 202649USD 28.67+14.1%
Provisional evidence
News subjects
What is shaping the score
Deals and strategy626 stories · 46%
Earnings385 stories · 38%
Market update501 stories · 8%
Analyst action501 stories · 8%
Source mix
Where the evidence comes from
MarketBeat653 stories · 23%
Simply Wall Street302 stories · 15%
Simply Wall St.541 stories · 8%
grafa.com501 stories · 8%
marketscreener.com501 stories · 8%
GlobeNewswire501 stories · 8%
Business in Vancouver501 stories · 8%
Recurring subjects
Subjects appearing most often
Mergers And Acquisitions2Life Sciences2Earnings2Fourth Quarter1Financial Guidance1Finance1Earnings Release1Biotech1Acquisition1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
11 May50 neutral16 Oct 04:35
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 16 Oct 04:35 | 48 | +0 | 25/100 (-5) | 13 (0) | Provisional |
| 12 Oct 23:59 | 48 | -4 | 30/100 (+7) | 13 (+1) | Provisional |
| 09 Oct 23:59 | 52 | +0 | 23/100 (-1) | 12 (+1) | Provisional |
| 08 Oct 23:59 | 52 | -2 | 24/100 (-8) | 11 (+2) | Provisional |
| 02 Oct 23:59 | 54 | +4 | 32/100 (+32) | 9 (+1) | Provisional |
| 28 Sep 23:59 | 50 | +0 | 0/100 (-15) | 8 (0) | Insufficient |
| 25 Sep 23:59 | 50 | +0 | 15/100 (0) | 8 (-2) | Provisional |
| 24 Sep 23:59 | 50 | -1 | 15/100 (-1) | 10 (0) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 13 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Earnings1 story
72.4%0.0%
Deals and strategy1 story
0.0%27.6%
Each side uses the same scale: 0–72.4% of the retained directional evidence.
Where the influence comes from
72.4%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
25/100 tone
72.4% of directional evidence
High story strength
Scoring detailsDirect company coverage
- Published
- 12 Oct 2026 08:50
- News subject
- Earnings
- Why this score
- Missed expectations
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- High · 65/100
- 30-day weight
- 72.4% of directional evidence · 3.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Zymeworks (ZYME) Could Be 39% Undervalued On 2026 Revenue Guidance And CIO Hire
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 09 Oct 2026 03:21
- News subject
- Earnings
- Why this score
- Positive valuation view
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Zymeworks Q3 2026 Earnings Date and Estimates
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Oct 2026 22:45
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.2d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Revenue Guidance Might Change The Case For Investing In Zymeworks (ZYME)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 08 Oct 2026 19:06
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
75/100 tone
Zymeworks has completed its acquisition of Theravance Biopharma for $17 per share, gaining profit-sharing rights and royalties for YUPELRI. This transaction is expected to boost Zymeworks' 2026 revenue to between $278 million and $292 million, with adjusted EBITDA projected at $114 millio…
27.6% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Zymeworks has completed its acquisition of Theravance Biopharma for $17 per share, gaining profit-sharing rights and royalties for YUPELRI. This transaction is expected to boost Zymeworks' 2026 revenue to between $278 million and $292 million, with adjusted EBITDA projected at $114 million to $128 million. The acquisition was financed through a $350 million non-recourse note and existing cash.
- Published
- 02 Oct 2026 23:02
- News subject
- Deals and strategy
- Why this score
- Guidance raised
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 56/100
- 30-day weight
- 27.6% of directional evidence · 13.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceLife SciencesMergers And Acquisitions
—Unscored
Deals and strategyNot used in direction
Zymeworks Completes Theravance Acquisition Deal
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 14:20
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
(ZYME) Zymeworks Expects 2026 Revenue Range $278M - $292M
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 28 Sep 2026 10:32
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Deals and strategyNot used in direction
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
Zymeworks Inc. Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-te…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Zymeworks Inc. Acquisition diversifies durable cash flows and advances Zymeworks' strategy to build a productive R&D company with a growing portfolio of revenue-generating assets YUPELRI® expected to contribute immediately accretive revenue and cash flow to Zymeworks with base case mid-teens IRR Zymeworks to retain existing commercial organization supporting YUPELRI hospital promotion The Company expects total revenue, including collaboration revenue from YUPELRI, for 2026 to be between $278 million and $292 million and 2026 Adjusted EBITDA to be between $114 million and $128 million Conferenc
- Published
- 28 Sep 2026 10:00
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
AcquisitionBiotechEarningsEarnings ReleaseFinancial GuidanceFourth Quarter
—Unscored
Deals and strategyNot used in direction
Vancouver biotech Zymeworks closes US$929M Theravance deal
Zymeworks Inc., a Vancouver-based biotech company, has finalized its acquisition of Theravance Biopharma Inc. for approximately US$929 million. This strategic move diversifies Zymeworks' portfolio beyond cancer treatments by adding commercial assets like Yupelri, royalty streams, and drug…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Zymeworks Inc., a Vancouver-based biotech company, has finalized its acquisition of Theravance Biopharma Inc. for approximately US$929 million. This strategic move diversifies Zymeworks' portfolio beyond cancer treatments by adding commercial assets like Yupelri, royalty streams, and drug-development assets, including access to US$2.5 billion in Irish tax attributes. The acquisition aligns with CEO Kenneth Galbraith's goal of expanding the company's drug portfolio.
- Published
- 25 Sep 2026 11:54
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 20.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Life SciencesMergers And Acquisitions
—Unscored
Market updateNot used in direction
Zymeworks Inc. (ZYME) Stock Price, News, Quote & History
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 15:38
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.5d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Deals and strategyNot used in direction
What Does the Theravance Acquisition Add for Zymeworks (NASDAQ:ZYME)?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 12:30
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 21.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Deals and strategyNot used in direction
Zymeworks Completes Acquisition of Theravance Biopharma
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 23 Sep 2026 20:35
- News subject
- Deals and strategy
- Why this score
- No clear directional signal in the available text
- Company focus
- Shared story · 78%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 22.3d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
Zymeworks Inc. (NASDAQ:ZYME) Receives Average Rating of "Moderate Buy" from Brokerages
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 20 Sep 2026 08:34
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 25.8d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
Earlier company news
ZYME news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 43 older ZYME headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to ZYME, but the headline and available text are not mainly about Zymeworks Inc. Common Stock. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of ZYME sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.